Saak V. Ovsepian on Scant α-Secretase Compensation for BACE Inhibition in Monkeys

COMMENT A very interesting finding, indeed! saak.ovsepian 0

Mike Miguel Pappolla on Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.

COMMENT This study is most interesting. It gives strong evidence that manipulation of the innate immune system is an important therapeutic target for AD. The authors have shown that stimulation of innate immunity via TLR9 leads to reduction in both Aβ and tau-rel

Mike Miguel Pappolla on In Aging Brain, Blood-Brain Barrier Starts Leaking in Hippocampus

COMMENT This is a very interesting concept. Almost three decades ago, we postulated the same hypothesis, based on histologic analysis of aged brains, demonstrating a blood brain barrier (BBB) breakdown and leakage of serum proteins in aged (but not young) human b

Andy Shih on Smooth Muscle Cells, Not Pericytes, Control Brain Blood Flow

COMMENT The study by Hill et al. is a beautiful illustration of how structure predicts function. As Dr. Attwell has pointed out, a primary controversy here is a difficulty in identifying cells that reside at the junction between arterioles and capillaries. We rec

Babak Tousi on Dementia with Lewy Bodies: Is the Research Ready For Clinical Trials

COMMENT This is an excellent summary to an already successful meeting. Kudos to Alzforum for showing us the art of writing a powerful summary. Batous_148501 0

Takaomi Saido on Blood NfL Looks Good as Progression and Outcome Marker

COMMENT It is interesting, and appers logical, that NfL levels correlate better with intracellular than with extracellular pathology. saido 0

Charlie Carroll on GeneMatch Registry Recruits Subjects for Prevention Trials

COMMENT I want to say "thanks" to scientists for developing tools that can identify people at greatest risk for the disease, and expedite their recruitment. This is great work. maryjsmith350_213486 0

Kumar Sambamurti on Field Loses Another Pioneer with Passing of Allen Roses, 73

COMMENT Following up on Jeanne's request for reminiscences, I recall that Allen's discussion with song and dance was entertaining and informative. Steve Younkin was there, too. I remember Dale showing a civil war picture and pointing to a gun and statin

Shawn Ferguson on Transport Breakdown Maroons BACE1 in Synapses, Boosts Aβ

COMMENT This study provides interesting new insights into the possible disease relevance of the accumulation of endolysosomal organelles within the dystropic axons that surround amyloid plaques. In a parallel effort, my group has recently identified a distinct JI

A. David Smith on Lancet Commission Claims a Third of Dementia Cases Are Preventable

COMMENT The Lancet Commission report is an heroic achievement but it was rather selective in the risk factors that it reported and which formed the basis of the widely-cited claim that more than a third of dementia cases might be prevented if all the modifiable r

William Rosenblum on Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

COMMENT Aducanumab may work because it reduces both insouble and soluble Abeta. However it may be incorrect to believe that the beneficial effect can only be manifest in early or prodromal disease because there is too much damage in more advanced cases. Instead i

Jeanne Loring on Treat IBD, Dodge PD? Epidemiology Ties Parkinson’s to Inflammation

COMMENT These findings were was novel to me, and show how the immune system is always surprising us. Systemic inflammation needs to be taken into account when considering cell-based therapy. There are multiple clinical trials planned for treatment of Parkinson’s

Joseph Castellano on Colleagues Mourn Loss of Rahul Desikan, Age 41, to ALS

COMMENT I met Rahul at a conference for early investigators several years back, and we all found it easy to become his colleague and friend. I was struck by his seemingly boundless energy, intelligence, and creativity. It's difficult for me to process the lo

Jürgen Götz on Aducanumab Approved to Treat Alzheimer’s Disease

COMMENT therapeutic outcomes. —Gerhard Leinenga is co-author of this comment. j.goetz 0 A comparative study of the

Martin Ingelsson, Dag Sehlin on Double Whammy: APP Uppsala Deletion Ups Aβ and Its Aggregation Propensity

COMMENT We appreciate the insightful comment by Drs. Ezzat and Espay and are grateful that our colleagues